These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Expression of fetal antigens and tumor-specific antigens in SV40-transformed cells. I. Serological analysis of the antigenic specificities. Ting CC; Ortaldo JR; Herberman RB Int J Cancer; 1973 Sep; 12(2):511-8. PubMed ID: 4134537 [No Abstract] [Full Text] [Related]
4. Immune response to polyoma tumor cells in mice. I. Magnitude and specificity of the in vitro cellular cytotoxicity elicited by immunization with graded numbers of tumor cells. Walia AS; Lamon EW J Natl Cancer Inst; 1977 Jun; 58(6):1671-5. PubMed ID: 194042 [No Abstract] [Full Text] [Related]
5. Potentiation of cytotoxic T-cell function by virus. Reinisch CL; Schlossman SF J Natl Cancer Inst; 1976 Dec; 57(6):1277-81. PubMed ID: 63565 [TBL] [Abstract][Full Text] [Related]
6. Cytolytic microassays and studies of SV40 tumor-specific transplantation antigen. Smith RW; Mora PT Virology; 1972 Oct; 50(1):233-46. PubMed ID: 4343110 [No Abstract] [Full Text] [Related]
8. Studies on the specificity of in vitro induced lymphocytotoxicity to SV40-transformed fibroblasts. Warnatz H; Krapf F J Immunol; 1976 Sep; 117(3):981-5. PubMed ID: 182884 [TBL] [Abstract][Full Text] [Related]
9. Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor. Howell SB; Dean JH; Law LW Int J Cancer; 1975 Jan; 15(1):152-69. PubMed ID: 236258 [TBL] [Abstract][Full Text] [Related]
10. Cell-mediated immunity to virus-induced tumors: generation of lymphocytes sensitized to specific transplantation antigen in mouse cells infected with papovavirus SV40. Tevethia SS; Tevethia MJ Prog Med Virol; 1975; 21():103-17. PubMed ID: 174151 [No Abstract] [Full Text] [Related]
11. A requirement for three cell types for in vitro generation of specific secondary cell-mediated cytotoxic response against SV40-induced tumor-associated antigens in mice. Glaser M Cell Immunol; 1980 Feb; 49(2):415-20. PubMed ID: 6243517 [No Abstract] [Full Text] [Related]
12. Expression of fetal antigens and tumor-specific antigens in SV40-transformed cells. II. Tumor transplantation studies. Ting CC; Rodrigues D; Herberman RB Int J Cancer; 1973 Sep; 12(2):519-23. PubMed ID: 4134567 [No Abstract] [Full Text] [Related]
13. Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Glaser M Cell Immunol; 1979 Dec; 48(2):339-45. PubMed ID: 228870 [No Abstract] [Full Text] [Related]
14. H-2 region product as determinant in immune cytolysis of syngeneic tumour cells by anti-MSV T lymphocytes. Gomard E; Duprez V; Henin Y; Levy JP Nature; 1976 Apr; 260(5553):707-9. PubMed ID: 177884 [No Abstract] [Full Text] [Related]
15. The importance of dose and proliferation of SV40-transformed cells with different oncogenic potentials to the level of tumor immunity. Stillström J Int J Cancer; 1974 Mar; 13(3):273-85. PubMed ID: 4362607 [No Abstract] [Full Text] [Related]
16. The immunopathology of SV40-induced transformation. Mora PT Springer Semin Immunopathol; 1982; 5(1):7-32. PubMed ID: 6314571 [No Abstract] [Full Text] [Related]
17. Reversion in hybrids between SV40-transformed hamster and mouse cells. Wiblin CN; Macpherson I Int J Cancer; 1973 Jul; 12(1):148-61. PubMed ID: 4364267 [No Abstract] [Full Text] [Related]
19. Study by the isotopic antiglobulin technique of a cross-reacting murine antibody produced by immunization with a syngeneic SV40 tumor. Burdick JF; Stemple D; Wells SA Int J Cancer; 1973 Sep; 12(2):474-84. PubMed ID: 4365462 [No Abstract] [Full Text] [Related]
20. Central problems in tumor immunology, 1976. Weiss DW Isr J Med Sci; 1976; 12(4-5):281-7. PubMed ID: 1084878 [No Abstract] [Full Text] [Related] [Next] [New Search]